Lumos Diagnostics Holdings Limited LDXHF

Company Overview

Lumos Diagnostics Holdings Limited is an Australian-based point-of-care (POC) diagnostics company focused on developing, manufacturing, and commercializing rapid diagnostic technologies. The company operates in the in-vitro diagnostics and medical technology industries, with a primary emphasis on rapid antigen and lateral flow testing platforms used in healthcare, pharmaceutical, and consumer applications. Lumos generates revenue through the sale of diagnostic products, assay development services, manufacturing services, and licensing or commercialization partnerships with healthcare and biotechnology companies.

The company’s core business lines include proprietary rapid diagnostic products, contract assay development, and manufacturing services for third-party diagnostic companies. Its technology portfolio centers on lateral flow immunoassay platforms and reader-enabled diagnostics designed to support decentralized testing environments such as physician offices, clinics, pharmacies, and at-home testing markets. Lumos has evolved from a diagnostics development and manufacturing specialist into a broader commercial diagnostics business through acquisitions, product commercialization initiatives, and expansion into regulated international markets. The company is recognized for its integrated model combining assay development, clinical validation, regulatory expertise, and manufacturing capabilities within a single organization.